Defining Overexpression of MYBL2 as a Driver of Lethal Prostate Cancer

Abstract

Due to inevitable therapeutic resistance, prostate cancer remains a lethal disease, so is critical to delineate mechanisms underlying therapeutic resistance to implement novel treatments that will extend patient survival and quality of life. We hypothesize MYBL2 over-expression facilitates resistance through a mechanism involving induction of lineage plasticity. We will test this hypothesis and determine novel treatment strategies for MYBL2 high prostate cancers and validate the power of MYBL2 expression/activity to predict ADT resistance in prostate cancer samples.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2022
Accession Number
AD1177033

Entities

People

  • Leigh Ellis

Organizations

  • Cedars-Sinai Medical Center

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Cell Line
  • Cells
  • Department Of Defense
  • Gene Expression
  • Genes
  • Genetics
  • Genotypes
  • Maryland
  • Neoplasms
  • Professional Development
  • Prostate
  • Prostate Cancer
  • Resistance
  • Survival
  • Three Dimensional
  • Two Dimensional

Fields of Study

  • Medicine

Readers

  • Prostate Cancer Biology.
  • Systems Analysis and Design